Pricing and Paying for Cancer Drugs: Policy Options for Fixing A Broken System

Area of Science:

• Health Economics
• Oncology
• Health Policy

Background:

• The current US system for cancer drug pricing and reimbursement is fundamentally flawed.
• High costs are evident in overall spending, advanced therapies like CAR T-cell, and new drugs with minimal benefits.
• Increasing patient copayments exacerbate affordability issues.

Purpose of the Study:

• To identify the primary drivers of high cancer drug expenditures in the US.
• To analyze how current payment policies distort physician incentives and devalue treatment options.
• To explore potential policy solutions for reforming cancer drug pricing and payment.

Main Methods:

• Review of existing literature on cancer drug spending and pricing.
• Analysis of US healthcare payment policies related to oncology.
• Examination of value-based care principles in cancer treatment.

Main Results:

• The US cancer drug market is characterized by unsustainable cost increases.
• Payment policies fail to adequately consider the comparative value of different cancer treatments.
• Physician incentives are often misaligned with cost-effective and value-driven prescribing.

Conclusions:

• The US cancer drug pricing and payment system requires urgent reform.
• Policy interventions should aim to align drug prices with therapeutic value and improve affordability.
• Addressing systemic issues is crucial for sustainable and equitable cancer care.